

**Table S1****Clinicopathological characteristics according to CD68 and CD163 QIF scores in cohort A**

<b>COHORT A</b>	<b>CD68 Low</b>	<b>CD68 High</b>	<b>p-value</b>	<b>CD163 Low</b>	<b>CD163 High</b>	<b>p-value</b>
<b>ER</b>			0.95			<b>0.002</b>
<b>ER Negative</b>	34	38		16	37	
<b>ER Positive</b>	60	66		51	40	
<b>PR</b>			0.26			0.05
<b>PR Negative</b>	34	48		20	35	
<b>PR Positive</b>	55	56		45	40	
<b>HER2</b>			0.77			0.09
<b>HER2 Negative</b>	24	38		19	27	
<b>HER2 Positive</b>	6	8		1	7	
<b>Size</b>			<b>0.08</b>			0.09
<b>&lt;2cm</b>	73	62		48	43	
<b>&gt;2 cm</b>	34	47		26	37	
<b>Age</b>			0.5			0.09
<b>&lt;50 Years</b>	37	44		24	34	
<b>50 or &gt;50 years</b>	80	69		61	48	
<b>LN Status</b>			0.16			
<b>LN neg</b>	56	65		68	64	<b>0.001</b>
<b>LN pos</b>	9	23		1	11	
<b>Grade</b>			0.33			0.53
<b>1or 2</b>	26	40		19	30	
<b>3</b>	21	46		15	31	
<b>Recurrence</b>			0.11			0.11
<b>Yes</b>	86	93		86	93	
<b>No</b>	32	21		32	21	

**Table S2**

**Clinicopathological characteristics according to MMP-9 QIF scores in CD68 and CD163 compartments in cohort A**

<b>COHORT A</b>	<b>MMP-9 Low in CD68+/CD163+</b>	<b>MMP-9 High in CD68+/CD163+</b>	<b>p-value</b>	<b>MMP-9 Low in CD68+</b>	<b>MMP-9 High in CD68+</b>	<b>p-value</b>
<b>ER</b>						
<b>ER Negative</b>	17	36	<b>0.02</b>	18	35	<b>0.02</b>
<b>ER Positive</b>	47	44		48	43	
<b>PR</b>						0.07
<b>PR Negative</b>	18	37	<b>0.03</b>	20	35	
<b>PR Positive</b>	37	42		44	41	
<b>HER2</b>						0.5
<b>HER2 Negative</b>	22	24		23	23	
<b>HER2 Positive</b>	2	6	0.21	3	5	
<b>Size</b>			0.83			0.25
<b>&lt;2cm</b>	42	49		46	45	
<b>&gt;2 cm</b>	28	25		26	37	
<b>Age</b>			0.17			0.14
<b>&lt;50 Years</b>	24	34		24	34	
<b>50 or &gt;50 years</b>	58	58		59	50	
<b>LN Status</b>			0.8			0.8
<b>LN neg</b>	60	72		61	71	
<b>LN pos</b>	5	7		6	6	
<b>Grade</b>			0.24			0.18
<b>1 or 2</b>	17	32		19	30	
<b>3</b>	11	35		12	34	
<b>Recurrence</b>			0.22			0.44
<b>Yes</b>	24	18		23	19	
<b>No</b>	59	68		61	66	

**Table S3**

**Clinicopathological characteristics according to CD68 and CD163 QIF scores in cohort B**

<b>COHORT B</b>	<b>CD68 Low</b>	<b>CD68 High</b>	<b>p-value</b>	<b>CD163 Low</b>	<b>CD163 High</b>	<b>p-value</b>
<b>Size</b>			0.18			0.53
<2cm	15	10		12	11	
>2 cm	20	26		19	24	
<b>Age</b>			0.12			0.5
<50 Years	14	25		17	19	
50 or >50 years	27	20		20	23	
<b>LN Status</b>			0.25			0.51
LN neg	11	4		9	4	
LN pos	8	7		8	6	
<b>Grade</b>			0.94			0.31
1 or 2	11	12		11	9	
3	23	26		20	28	
<b>Stage</b>			0.38			0.6
I-II	14	15		14	2	
III-IV	1	3		12	1	

**Table S4**  
**Clinicopathological characteristics according to MMP-9 QIF scores in CD68 and CD163 compartments in cohort B**

<b>COHORT B</b>	<b>MMP-9 Low in CD68+/CD163+</b>	<b>MMP-9 High in CD68+/CD163+</b>	<b>p-value</b>	<b>MMP-9 Low in CD68+</b>	<b>MMP-9 High in CD68+</b>	<b>p-value</b>
<b>Size</b>			0.06			0.13
<2cm	14	7		13	8	
>2 cm	18	25		18	25	
<b>Age</b>			0.24			0.25
<50 Years	15	19		15	19	
50 or >50 years	21	21		20	22	
<b>LN Status</b>			0.42			0.45
LN neg	10	7		11	5	
LN pos	4	6		6	5	
<b>Grade</b>			<b>0.01</b>			<b>0.009</b>
1or 2	13	5		13	5	
3	18	29		17	30	
<b>Stage</b>			0.76			0.7
I-II	15	2		15	10	
III-IV	11	1		2	2	